Insights
One specific point per article, drawn from what several experts said across different podcasts: where they agree, where they don't, and what to do with it. Every claim links back to the episode it came from.
Short on time? Cheat sheets and flashcards for the insights.
FiltersLongevityArtificial IntelligenceAi and ProgrammingSupplements Peptides HormonesClear
Pick as many as you like: any of them matches within a group.
9 insights
Growth hormone: the youth hormone that may not lengthen life
Clinics offer growth hormone and drugs that release it to restore youthful muscle and skin, and Kyle Gillett and Craig Koniver describe using them, yet David Sinclair notes that lower growth signaling goes with longer life and Huberman lists the risks of injecting it. The contrast shows why feeling younger and living longer are not always the same goal.
Is prompting a lasting skill or a passing phase?
Amanda Askell and the Cursor team treat prompt writing as careful craft, Fei-Fei Li and Manolis Kellis see it as a new literacy, and Aravind Srinivas says good products should remove the need for it. The answer tells learners how much effort to invest in the skill.
AI agents at work: what changes when models act on their own
DHH runs parallel coding agents, the Cursor team describes agents working in a shadow workspace, Anthropic released a model that operates a computer, and Kokotajlo recounts a swarm that got out of hand. Moving from answering to acting multiplies both the usefulness and the risk.
AI regulation or regulatory capture? Amodei, Altman, Musk and Andreessen
Amodei and Altman argue that governments must set rules for frontier AI, Musk has pushed for oversight, and Andreessen says such rules would lock in the largest companies. Each side accuses the other of serving its own interest, so readers need the actual arguments to judge.
Peptides: promising, poorly tested and often gray-market
Craig Koniver uses peptides clinically, while Huberman's review stresses thin human evidence, tumor questions and sourcing risks, and his growth hormone episode warns about injections. It shows why physician oversight matters in a fast-growing, loosely regulated field.
Which blood tests to get, and when to start
Casey Means, Sara Gottfried, Kyle Gillett and Peter Attia each lay out biomarkers worth tracking by age and sex, from glucose and insulin to hormones and lipids. Starting a baseline early lets you catch drift years before disease.
Can a pill slow aging? Sinclair's optimism versus Attia's skepticism
Sinclair frames aging as a treatable disease and is bullish on resetting cellular age, while Attia's reviews of metformin and NAD boosters find the evidence much weaker than the hype. Seeing both views side by side helps readers judge whether expensive longevity compounds are worth their money yet.
Food first, supplements second, with one micronutrient caveat
Attia and Mosconi stress that supplements cannot make up for poor diet, sleep and exercise, while Rhonda Patrick argues that common deficiencies in magnesium, vitamin D and omega-3s are worth correcting directly. Together they suggest a sensible order: fix foundations, then fill documented gaps.
Hormones and longevity: menopause, optimization and where experts draw lines
Mosconi links menopause to women's Alzheimer's risk, while Attia and Koniver discuss hormone optimization as a longevity lever with differing enthusiasm. Midlife hormone changes turn out to matter well beyond fertility and deserve informed attention.